Bestowed annually, the Bloom Burton Award honours an individual scientist, inventor, executive, entrepreneur, industry leader, or policy maker who made the greatest contribution to Canada’s innovative healthcare industry in the previous year. Nominees will be accepted from any of the biotechnology, pharmaceutical, medical device, diagnostic/imaging, research instrumentation, consumer health, services or healthcare IT sectors, and equal consideration will be given to contributions across any stage of development – from discovery to commercial end markets.

The Bloom Burton Award winner will be chosen from an esteemed panel of judges, all of whom are respected international leaders in healthcare investment, entrepreneurship and journalism.

Four Seasons Hotel  60 Yorkville Avenue

6:00PM  |  Black Tie  |  Purchase tickets here

Please contact group.toronto@fourseasons.com for information on our room block


Our finalists, Gilbert Godin and Greg Gubitz, David Lickrish and Poul Sorensen will be celebrated for their incredible contributions to the Canadian healthcare sector.

Each of the finalists will receive a $25,000 cash prize, and a single winner will have the honour of being the 2019 Bloom Burton Award recipient.


Mr. Gilbert Godin’s career in Healthcare and Life Sciences spans across more than 3 decades in a variety of leadership and operational roles in North America and Europe.   

Mr. Godin is a co-founder and the President and Chief Operating Officer of HLS Therapeutics Inc. (TSX:HLS),  a Canadian based, North American focused specialty pharmaceutical company.

Prior to co-founding HLS, Mr. Godin was CEO of Duchesnay USA where he created the team that brought Duchesnay’s first product to the US OBGYN market. Before that, Mr. Godin was Executive Vice President and Chief Operating Officer of Biovail Corporation; formerly Canada’s largest publicly traded pharmaceutical company. In that capacity, he oversaw Business Operations, R&D, Plant Operations, Regulatory Affairs, and Licensing until the merger of Biovail and Valeant Pharmaceutical International Inc. (TSX:VRX) at the end of 2010.  Prior to Biovail, Mr. Godin spent 7 years at MDS Pharma Services, leading a team of 4,000 scientists in 42 countries as President of the global Contractual Research Organization for the pharmaceutical market. Before joining MDS Pharma, Mr. Godin held Executive roles at Schering Plough in Canada and in Europe (France) where he directed the strategic and commercial deployment in the field of viral hepatitis, and at L’Oreal Healthcare in commercial and technical leadership roles.

Mr. Godin attended Sherbrooke University where he received a Bachelor in Mechanical Engineering in 1982 and the John Molson School of Business where he received a Master in Business Administration in 1992.


Mr. Gregory Gubitz is a seasoned life science executive and business lawyer, with significant transaction, investment and operating experience.  

Mr. Gubitz is a co-founder and the Chief Executive Officer of HLS Therapeutics Inc. (TSX:HLS), a Canadian based, North American focused specialty pharmaceutical company.

Mr. Gubitz was Senior Vice President, Corporate Development and General Counsel of Biovail Corporation; formerly Canada’s largest publicly traded pharmaceutical company. In that capacity he was responsible for mergers & acquisitions and product acquisitions, culminating with the $7 billion merger of Biovail and Valeant Pharmaceutical International Inc. (TSX:VRX).  Prior to joining Biovail, for 10 years he was a senior executive with MDS Capital, a leading North American venture capital company, focused on healthcare. As Chief Operating Officer of MDS Capital, Mr. Gubitz was responsible for all operational aspects of the company with a total of $1 billion under management. Before joining MDS Capital, Mr. Gubitz was a partner at one of Canada’s leading international law firms, where he represented numerous public and private companies in a wide range of financings, mergers & acquisitions, joint ventures, and business transactions.

Mr. Gubitz attended McGill University where he received a Bachelor of Arts Degree in 1979 and a Bachelor of Laws Degree in 1982.  He was called to the Bar in the Province of Ontario in 1984.


David Lickrish is the Founder, CEO and Chairman of Highland Therapeutics Inc. and Chief Executive Officer of Ironshore Pharmaceuticals & Development, Inc., a subsidiary of Highland Therapeutics.

Prior to founding Highland Therapeutics, David worked in Finance as a Senior Equity Research Analyst covering the Global Pharmaceutical Industry where he became familiar with Attention Deficit Hyperactivity Disorder (ADHD) and the unmet clinical needs associated with it such as early morning functioning (EMF). David recognized EMF as a significant challenge in the treatment of ADHD and used the knowledge garnered throughout his career to pursue potential solutions.

Transitioning from the world of finance to healthcare, David dedicated himself to the creation of a patented, oral, once-daily drug-delivery technology now known as DELEXIS®. This novel technology was designed to enable the administration of medicines in the evening with the objective of achieving a therapeutic effect early the next morning and lasting throughout the day.

Under his leadership, Ironshore has grown from a start-up research and development organization to an international pharmaceutical company with a proprietary drug-delivery technology and multiple late-stage drugs under development. Ironshore recently launched FDA-approved JORNAY PMTM indicated for the treatment of ADHD in patients 6 years and older in the United States. JORNAY PM is the first and only ADHD stimulant that is dosed in the evening and is working when patients wake up and lasts throughout the day and into the evening.   

David studied Microbiology and Finance at the University of Guelph in Canada. He graduated with Honors and received his Bachelor of Commerce in International Economics and Finance. David has been a CFA Charter holder since 2001 and is the named inventor on more than 15 patents in the United States, Europe and Asia.


Dr. Poul Sorensen is a molecular pathologist and cancer biologist specializing in the genetics and biology of pediatric cancers. Dr. Sorensen holds the Johal Endowed Chair in Childhood Cancer Research at the University of British Columbia (UBC), and is Professor of Pathology at UBC.

Dr. Sorensen is a founding member of the AACR Pediatric Cancer Working Group. He is a principal investigator on the recently awarded Stand Up 2 Cancer Pediatric Cancer Dream Team grant focused on immunotherapeutic approaches to targeting high-risk childhood cancers. His group runs several major components of this prestigious award, including the Pathology Core.

Dr. Sorensen’s laboratory, located at the BC Cancer Research Centre, focuses on using both genetic approaches (such as next-generation sequencing) and biochemical methods (e.g. proteomics) to identify deregulated signaling cascades in childhood cancer cells. His group has discovered many novel translocation associated alterations in childhood cancer (e.g. Knezevich et al, Nat Genet, 1998, Tognon et al, Cancer Cell, 2002). Moreover, the group has extensive renown in utilizing genetic findings as a means to characterize relevant cancer biology (e.g. Evdokimova et al, Cancer Cell, 2009, Mendoza-Naranjo et al, EMBO Mol Med, 2013, Leprivier et al, Cell, 2013, Daugaard et al, Nat Comm, 2013, Somasekharan et al, J Cell Biol, 2015, and El-Naggar et al, Cancer Cell, 2015).

Current work is focused on how cancer cells respond to acute stress. The overarching hypothesis is that adaptation to such stresses through altered mRNA translation and protein synthesis leads to tumour cell clonal selection and metastasis. The group therefore utilizes a variety of proteomic and other techniques to probe the “translatome” of stressed tumour cells to identify new targets for therapy in aggressive human solid tumours.


Our esteemed panel of judges are respected international leaders in healthcare investment, entrepreneurship and journalism:

  • Michael Altman, Managing Director, Perceptive Advisors
  • Karen Bernstein, Co-Founder and Chairman, BioCentury Inc.
  • Cecilia Gonzalo, Partner, Oberland Capital
  • Carl Gordon, Partner and Co-Head of Global Private Equity, OrbiMed Advisors
  • Dennis Purcell, Founder and Senior Advisory, Aisling Capital
  • Melinda Richter, Global Head of Johnson & Johnson Innovation, JLABS
  • Mayukh Sukhatme, Chief Business Officer, Roivant Pharma






Brian Bloom

Tel: (416) 640-7580